Senate Passes Defense Bill With BIOSECURE Act, Advancing China-Focused Biotech Curbs

Overview

• The Senate approved the National Defense Authorization Act with an amendment that embeds an updated BIOSECURE provision targeting certain China-linked biotech ties.
• Conference negotiators must resolve differences because the House’s earlier defense bill did not include the BIOSECURE language.
• The proposal aims to bar federal contracts and funding for designated biotechnology companies of concern and to protect U.S. health and genetic data.
• Supporters and analysts say the measure could hand the president additional leverage over pharmaceutical and biotech firms, including on drug‑pricing pressure.
• Industry watchers point to potential gains for Indian CDMOs as U.S. buyers seek non‑Chinese suppliers, citing Divi’s Labs, Syngene, Neuland Labs, Jubilant Pharmova, Piramal Pharma, and Laurus Labs.